Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, McKenney JL, Mercier RY, Pfeffer MA, Selhub J; FAVORIT Study Investigators.

Am J Kidney Dis. 2009 Jan;53(1):121-8. doi: 10.1053/j.ajkd.2008.08.010. Epub 2008 Nov 20.

2.

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.

Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J; FAVORIT Investigators.

Am Heart J. 2006 Sep;152(3):448.e1-7.

PMID:
16923411
3.

Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Dad T, Tighiouart H, Joseph A, Bostom A, Carpenter M, Hunsicker L, Kusek JW, Pfeffer M, Levey AS, Weiner DE.

Am J Kidney Dis. 2016 Aug;68(2):277-86. doi: 10.1053/j.ajkd.2016.01.019. Epub 2016 Mar 2.

PMID:
26947217
4.

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.

Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators.

JAMA. 2007 Sep 12;298(10):1163-70. Erratum in: JAMA. 2008 Jul 9;300(2):170.

PMID:
17848650
5.

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M.

Circulation. 2011 Apr 26;123(16):1763-70. doi: 10.1161/CIRCULATIONAHA.110.000588. Epub 2011 Apr 11.

6.

Cognitive dysfunction and depression in adult kidney transplant recipients: baseline findings from the FAVORIT Ancillary Cognitive Trial (FACT).

Troen AM, Scott TM, D'Anci KE, Moorthy D, Dobson B, Rogers G, Weiner DE, Levey AS, Dallal GE, Jacques PF, Selhub J, Rosenberg IH; FACT Study Investigators.

J Ren Nutr. 2012 Mar;22(2):268-76.e1-3. doi: 10.1053/j.jrn.2011.07.009. Epub 2011 Dec 6.

7.

Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.

Nanayakkara PW, Kiefte-de Jong JC, ter Wee PM, Stehouwer CD, van Ittersum FJ, Olthof MR, Teerlink T, Twisk JW, van Guldener C, Smulders YM.

Am J Kidney Dis. 2009 Jan;53(1):41-50. doi: 10.1053/j.ajkd.2008.06.016. Epub 2008 Sep 11.

PMID:
18786751
8.

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.

Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE.

JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027.

9.

Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial.

Xu X, Qin X, Li Y, Sun D, Wang J, Liang M, Wang B, Huo Y, Hou FF; investigators of the Renal Substudy of the China Stroke Primary Prevention Trial (CSPPT).

JAMA Intern Med. 2016 Oct 1;176(10):1443-1450. doi: 10.1001/jamainternmed.2016.4687.

PMID:
27548766
10.

Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.

Brady CB, Gaziano JM, Cxypoliski RA, Guarino PD, Kaufman JS, Warren SR, Hartigan P, Goldfarb DS, Jamison RL.

Am J Kidney Dis. 2009 Sep;54(3):440-9. doi: 10.1053/j.ajkd.2009.05.013. Epub 2009 Jul 23.

11.

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M.

JAMA. 2004 Feb 4;291(5):565-75.

PMID:
14762035
12.

Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.

Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygård O.

JAMA. 2008 Aug 20;300(7):795-804. doi: 10.1001/jama.300.7.795.

PMID:
18714059
13.

Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.

Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S; HOPE-2 Investigators.

Can J Cardiol. 2006 Jan;22(1):47-53.

14.

Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.

Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M.

Z Kardiol. 2004 Jun;93(6):439-53. Review.

PMID:
15252738
16.

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.

Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V.

BMJ. 2012 Jun 13;344:e3533. doi: 10.1136/bmj.e3533. Review.

17.

DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.

Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M; DACH-LIGA Homocystein e.V.

Clin Chem Lab Med. 2003 Nov;41(11):1392-403. Review. Erratum in: Clin Chem Lab Med. 2004 Jan;42(1):113-6.

PMID:
14656016
18.

Homocysteine or renal impairment: which is the real cardiovascular risk factor?

Potter K, Hankey GJ, Green DJ, Eikelboom JW, Arnolda LF.

Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1158-64. doi: 10.1161/ATVBAHA.108.162743. Epub 2008 Mar 20.

19.

Interventions for lowering plasma homocysteine levels in dialysis patients.

Nigwekar SU, Kang A, Zoungas S, Cass A, Gallagher MP, Kulshrestha S, Navaneethan SD, Perkovic V, Strippoli GF, Jardine MJ.

Cochrane Database Syst Rev. 2016 May 31;(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Review.

PMID:
27243372
20.

Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis.

Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, Xu X, Wang X.

Clin J Am Soc Nephrol. 2011 Mar;6(3):482-8. doi: 10.2215/CJN.05310610. Epub 2010 Nov 18.

Supplemental Content

Support Center